miR-630 functions as a tumor oncogene in renal cell carcinoma.
BACKGROUND
MicroRNAs (miRNAs) are non-coding RNAs that regulate multiple cell processes during cancer progression. Renal cell carcinoma (RCC) is a malignancy with a poor prognosis. In this study, we aimed to investigate the roles of miR-630 in RCC progression.


METHODS
Expression of miR-630 was evaluated by quantitative real-time polymerase chain reaction (qRT-PCR) in four renal cancer cell lines (786-O, ACHN, Caki-1, and Caki-2) and one normal human proximal tubule epithelial cell line (HK-2). Next, miR-630 inhibitor was used to inhibit miR-630 expression in 786-O cells. Finally, its effects on cell proliferation, apoptosis, migration, and invasion were evaluated.


RESULTS
The expression level of miR-630 was higher in renal cancer cell lines 786-O, ACHN, Caki-1, and Caki-2 than that in the normal renal cell line HK-2 (p < 0.05). Furthermore, a proliferation assay, apoptosis assay, migration assay and invasion assay were performed, and the results showed that down-regulation of miR-630 expression by miR-630 inhibitor significantly inhibited cell proliferation, migration, and invasion, which meanwhile induced cell apoptosis of the renal cancer cell line 786-O.


CONCLUSIONS
This is the first time that miR-630 expression has been shown to be associated with renal cancer progression, and down-regulation of miR-630 can inhibit tumor progression, which provides a potential therapeutic target for renal cancer treatment.
Department of Urology, Affiliated Hospital of Hebei University of Engineering, Handan, Hebei, China; Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Jian-Jun
JJ
Zhao
Department of Neurology, Handan Central Hospital, Handan, Hebei, China.
Peng-Jie
PJ
Chen
Department of Urology, Affiliated Hospital of Hebei University of Engineering, Handan, Hebei, China.
Rui-Qin
RQ
Duan
Department of Urology, Affiliated Hospital of Hebei University of Engineering, Handan, Hebei, China.
Ke-Ji
KJ
Li
Department of Urology, Affiliated Hospital of Hebei University of Engineering, Handan, Hebei, China.
Yu-Zhong
YZ
Wang
Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Yong
Y
Li
invasion; miR-630; migration; proliferation; renal cell carcinoma